Xaliproden

	WikiDoc Resources for Xaliproden
Articles
Most recent articles on Xaliproden Most cited articles on Xaliproden Review articles on Xaliproden Articles on Xaliproden in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Xaliproden Images of Xaliproden Photos of Xaliproden Podcasts & MP3s on Xaliproden Videos on Xaliproden
Evidence Based Medicine
Cochrane Collaboration on Xaliproden Bandolier on Xaliproden TRIP on Xaliproden
Clinical Trials
Ongoing Trials on Xaliproden at Clinical Trials.gov Trial results on Xaliproden Clinical Trials on Xaliproden at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Xaliproden NICE Guidance on Xaliproden NHS PRODIGY Guidance FDA on Xaliproden CDC on Xaliproden
Books
Books on Xaliproden
News
Xaliproden in the news Be alerted to news on Xaliproden News trends on Xaliproden
Commentary
Blogs on Xaliproden
Definitions
Definitions of Xaliproden
Patient Resources / Community
Patient resources on Xaliproden Discussion groups on Xaliproden Patient Handouts on Xaliproden Directions to Hospitals Treating Xaliproden Risk calculators and risk factors for Xaliproden
Healthcare Provider Resources
Symptoms of Xaliproden Causes & Risk Factors for Xaliproden Diagnostic studies for Xaliproden Treatment of Xaliproden
Continuing Medical Education (CME)
CME Programs on Xaliproden
International
Xaliproden en Espanol Xaliproden en Francais
Business
Xaliproden in the Marketplace Patents on Xaliproden
Experimental / Informatics
List of terms related to Xaliproden

Xaliproden
Clinical data
ATC code	N07XX03 (WHO) ;
Identifiers
	IUPAC name 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine;
CAS Number	135354-02-8 ;
PubChem CID	128919;
ChemSpider	114237 ;
UNII	V8QL94KNQO;
KEGG	D06327 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C24H22F3N
Molar mass	381.433 g/mol
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)c4cccc(/C3=C/CN(CCc2cc1ccccc1cc2)CC3)c4;
	InChI InChI=1S/C24H22F3N/c25-24(26,27)23-7-3-6-22(17-23)20-11-14-28(15-12-20)13-10-18-8-9-19-4-1-2-5-21(19)16-18/h1-9,11,16-17H,10,12-15H2 ; Key:WJJYZXPHLSLMGE-UHFFFAOYSA-N ;
(what is this?) (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Xaliproden (codenamed SR57746) is a drug which acts as a 5HT_1A agonist.^[1] It has neurotrophic and neuroprotective effects in vitro,^[2]^[3] and has been proposed for use in the treatment of several neurodegenerative conditions including amyotrophic lateral sclerosis (ALS)^[4] and Alzheimer's disease.^[5]

Development of xaliproden for these two indications was discontinued in 2007 following analysis of Phase III data. While the drug did show an effect on hippocampal volume (suggesting perhaps a slowing of cell loss), there was insufficient evidence for efficacy in counteracting Alzheimer's related cognitive decline. Similarly while there were some indicators of efficacy in ALS, including a small but clinically noteworthy effect on some functional parameters, the overall benefit did not reach statistical significance when results across several Phase III trials were averaged. Xaliproden remains under investigation for treatment of chemotherapy-induced peripheral neuropathy.^[6]^[7]

References

↑ Appert-Collin, A; Duong, FH; Passilly Degrace, P; Warter, JM; Poindron, P; Gies, JP (2005). "MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden". International journal of immunopathology and pharmacology. 18 (1): 21–31. PMID 15698508.
↑ Labie, C; Lafon, C; Marmouget, C; Saubusse, P; Fournier, J; Keane, PE; Le Fur, G; Soubrié, P (1999). "Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex". British Journal of Pharmacology. 127 (1): 139–44. doi:10.1038/sj.bjp.0702545. PMC 1566010. PMID 10369466.
↑ Duong, FH; Warter, JM; Poindron, P; Passilly, P (1999). "Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons". British Journal of Pharmacology. 128 (7): 1385–92. doi:10.1038/sj.bjp.0702910. PMC 1571767. PMID 10602316.
↑ Meininger, V; Bensimon, G; Bradley, WR; Brooks, B; Douillet, P; Eisen, AA; Lacomblez, L; Leigh, PN; Robberecht, W (2004). "Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials". Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. 5 (2): 107–17. doi:10.1080/14660820410019602. PMID 15204012.
↑ Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P (2002). "Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats". Invest Radiol. 37 (6): 321–7. doi:10.1097/00004424-200206000-00003. PMID 12021588.
↑ Susman, E (2006). "Xaliproden lessens oxaliplatin-mediated neuropathy". The lancet oncology. 7 (4): 288. doi:10.1016/S1470-2045(06)70639-8. PMID 16598880.
↑ Wolf, S; Barton, D; Kottschade, L; Grothey, A; Loprinzi, C (2008). "Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies". European journal of cancer (Oxford, England : 1990). 44 (11): 1507–15. doi:10.1016/j.ejca.2008.04.018. PMID 18571399.

[1] Appert-Collin, A; Duong, FH; Passilly Degrace, P; Warter, JM; Poindron, P; Gies, JP (2005). "MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden". International journal of immunopathology and pharmacology. 18 (1): 21–31. PMID 15698508.

[2] Labie, C; Lafon, C; Marmouget, C; Saubusse, P; Fournier, J; Keane, PE; Le Fur, G; Soubrié, P (1999). "Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex". British Journal of Pharmacology. 127 (1): 139–44. doi:10.1038/sj.bjp.0702545. PMC 1566010. PMID 10369466.

[3] Duong, FH; Warter, JM; Poindron, P; Passilly, P (1999). "Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons". British Journal of Pharmacology. 128 (7): 1385–92. doi:10.1038/sj.bjp.0702910. PMC 1571767. PMID 10602316.

[4] Meininger, V; Bensimon, G; Bradley, WR; Brooks, B; Douillet, P; Eisen, AA; Lacomblez, L; Leigh, PN; Robberecht, W (2004). "Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials". Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. 5 (2): 107–17. doi:10.1080/14660820410019602. PMID 15204012.

[5] Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P (2002). "Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats". Invest Radiol. 37 (6): 321–7. doi:10.1097/00004424-200206000-00003. PMID 12021588.

[6] Susman, E (2006). "Xaliproden lessens oxaliplatin-mediated neuropathy". The lancet oncology. 7 (4): 288. doi:10.1016/S1470-2045(06)70639-8. PMID 16598880.

[7] Wolf, S; Barton, D; Kottschade, L; Grothey, A; Loprinzi, C (2008). "Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies". European journal of cancer (Oxford, England : 1990). 44 (11): 1507–15. doi:10.1016/j.ejca.2008.04.018. PMID 18571399.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Clinical data

ATC code	N07XX03 (WHO)
Identifiers
IUPAC name 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine
CAS Number	135354-02-8^Y
PubChem CID	128919
ChemSpider	114237^N
UNII	V8QL94KNQO
KEGG	D06327^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₄H₂₂F₃N
Molar mass	381.433 g/mol
3D model (JSmol)	Interactive image
SMILES FC(F)(F)c4cccc(/C3=C/CN(CCc2cc1ccccc1cc2)CC3)c4
InChI InChI=1S/C24H22F3N/c25-24(26,27)23-7-3-6-22(17-23)20-11-14-28(15-12-20)13-10-18-8-9-19-4-1-2-5-21(19)16-18/h1-9,11,16-17H,10,12-15H2^N Key:WJJYZXPHLSLMGE-UHFFFAOYSA-N^N
^NY (what is this?) (verify)

Xaliproden

Overview

References

Navigation menu